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incremental cost per QALY gained is 21.074 reais. In HCV non-
1 genotype patients, PEG2B increases LY by 1.02 and QALY by
0.47 years in comparison to non-PEG. The incremental cost per
QALY gained is 15.057 reais. The weighted average incremen-
tal cost-effectiveness ratio, using population-based HCV geno-
type distribution estimates, for all genotypes was 17.832 per
QALY. CONCLUSIONS: Peginterferon alfa-2b (12KD)/
ribavirin are a cost-effective therapy for treatment of naive adults
with CHC compared with standard interferon alfa-2b/ribavirin,
regardless of HCV genotype.
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OBJECTIVES: To assess the cost-effectiveness of two treatment
strategies for reﬂux esophagitis (RE) in Finland: acute treatment
with esomeprazole 40mgqd followed by maintenance treatment
with 20mgqd, or acute treatment with pantoprazole 40mgqd
followed by maintenance treatment with 20mgqd. METHODS:
A decision analysis model was developed to compare the two
treatment strategies with regard to direct medical costs (drugs,
physician visits, investigations, procedures) and productivity
costs (absence from work and reduced productivity while at
work) using a 7-month time horizon. Probabilities for treatment
success were based on results from a large multinational, ran-
domised, double-blind clinical study of up to 8 weeks acute (n
= 3170) and 6 months maintenance (n = 2766) treatment of RE.
The proportion of patients with treatment success and an esti-
mated number of weeks with symptoms of gastro-esophageal
reﬂux disease (GERD) were used as effectiveness measures. Sen-
sitivity analyses were made by using upper and lower 95% con-
ﬁdence limits of the clinical study results, as well as by changing
patient management assumptions. RESULTS: The proportion of
patients with treatment success, deﬁned as healed RE within 8
weeks acute treatment and no relapse during subsequent main-
tenance treatment, was 83.4% and 69.6% for esomeprazole and
pantoprazole, respectively (i.e. an absolute difference of 13.8%).
This corresponded to 1.1 weeks less with GERD per patient by
using esomeprazole. In the base case analysis, the mean estimated
direct medical cost per patient was slightly lower for the
esomeprazole strategy (€33) and the estimated productivity loss
per patient was considerably lower for the esomeprazole strat-
egy (€114). Sensitivity analyses supported robustness of main
ﬁndings. CONCLUSION: The esomeprazole treatment strategy
was found to be cost-effective compared with the pantoprazole
treatment strategy, since esomeprazole provides better effective-
ness and savings in work productivity costs at similar or lower
direct medical costs.
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OBJECTIVES: A recent study has shown that 48 weeks treat-
ment with peginterferon alfa-2a (40KD) (PEGASYS) compared
with lamivudine leads to improved efﬁcacy in patients with
HBeAg-positive CHB. However, the cost effectiveness of 
peginterferon alfa-2a compared with lamivudine has not been
assessed. The current analysis was designed to assess the net
health consequences, costs and cost-effectiveness of 48 weeks of
peginterferon alfa-2a for the treatment of patients with HBeAg-
positive CHB, compared with shorter term (48 weeks) and
longer term (4 years) lamivudine treatment. METHODS: A cost-
utility analysis from a payer perspective using a state-transition
Markov model simulating the natural history of CHB. Clinical
inputs were taken from a randomized trial comparing peginter-
feron alfa-2a and lamivudine for the treatment of HBeAg-
positive CHB. A reference cohort of patients with mean age of
32 years and HBeAg-positive disease was used. Life expectancy,
quality-adjusted life years (QALY), lifetime direct health care
costs, and incremental cost-effectiveness ratios (ICERs) were 
estimated. RESULTS: Treatment with peginterferon alfa-2a 
compared with lamivudine (for 48 weeks) resulted in higher 
total costs, but more QALYs gained, yielding an ICER of
£8820/QALY gained. The ICER comparing the two treatments
does not exceed £15,400/QALY gained despite variation in each
parameter used in the analysis. In the analysis comparing 48
weeks of treatment with peginterferon alfa-2a versus 4 years of
treatment with lamivudine, the ICER was £10,100/QALY
gained. CONCLUSIONS: Deﬁned 48 weeks treatment with
peginterferon alfa-2a (40KD) (PEGASYS) compared with either
short-term or long-term lamivudine treatment in HBeAg-positive
patients offers life expectancy beneﬁts for cost effectiveness
ratios that are well below the commonly accepted cost-
effectiveness threshold in the UK.
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The two inﬂammatory bowel diseases (IBD), Ulcerative colitis
CD and Crohn’s disease UC are chronic relapsing diseases. As
the major part of the health care costs of IBD consists of hospi-
talizations and surgery, there is a great potential for novel ther-
apies to reduce costs and improve quality of life (QoL) if they
could reduce the relapse rate and maintain patients in remission.
A novel treatment option in these patients is the Granulocyte and
monocyte/macrophage apheresis (Adacolumn®). OBJECTIVES:
To estimate the cost-effectiveness of treating (CD) and (UC)
patients with Adacolumn® aphaeresis compared to standard
treatment. METHODS: We developed a Markov model for the
treatment of UC and CD. The model and our cost-effectiveness
application for CD and UC is based on four data sources: (a) an
uncontrolled clinical study of the ﬁrst 100 patients treated with
Adacolumn® apheresis for IBD in clinical practice [The Scandi-
navian study], (b) a cohort of 147 IBD patients treated with 
usual care from Denmark [Danish Crohn Colitis Database-
Copenhagen County)] including 1 304 patient years (c) prices of
health care and pharmaceuticals from Sweden, (d) and QALY
data from literature. RESULTS: Surgical operations and days in
hospital were reduced by %90 cent. The cost per QALY gained
by treating patients for three years with Adacolumn® is
US$19,015 for UC and US$70,142 for CD, respectively. CON-
CLUSION: The comparison between the usual care treatment
and the Adacolumn® treatment is based on the matching of two
cohorts. Our results will be compared with forthcoming data
from a randomized clinical trial. Compared to usual care Ada-
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column® treatment of moderate severe UC and CD patients is
associated with cost offsets for surgery, hospitalizations, outpa-
tient care and drugs and an increase of QALYs. The cost-effec-
tiveness ratios remain within the acceptable range for treatments
to be recommended for use in Sweden.
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OBJECTIVES: To assess cost-effectiveness of esomeprazole 
40mg (SEK 14.68 / tablet: EUR 1 = SEK 9.27, June 15, 2005)
once daily (od) versus omeprazole 20mgod at the lowest avail-
able generic drug price (SEK 4.32 / tablet) in the acute treatment
of reﬂux esophagitis (RE) in Sweden. METHODS: A decision
analysis model was used considering pooled effectiveness data
from comparative clinical studies and patient management
assumptions based on expert opinions. Results were analysed
using an 8-week time horizon and reported separately including
work productivity costs or direct medical costs (drugs, physician
contacts, investigations) only. Utility values associated with
having healed RE (0.84) or unhealed RE (0.69) were derived
from a study using the rating scale method in patients with
gastro-esophageal reﬂux disease (GERD). Estimates of GERD-
related work productivity loss (absence from work and reduced
productivity while at work) were derived from observed differ-
ences in productivity before and after treatment in another study.
A probabilistic sensitivity analysis (PSA) on direct medical 
costs was used to assess robustness of results, along with addi-
tional analyses extending the time horizon beyond 8 weeks. An
acceptable threshold of SEK 500,000 per quality-adjusted life
year (QALY) gained was used in the PSA. RESULTS: When
including direct medical costs only, the analysis resulted in mean
additional costs of around SEK 200,000 per QALY gained by
using the more effective acid inhibitory treatment strategy
(esomeprazole). The PSA on the probability of esomeprazole
treatment being below a SEK 500,000 per QALY gained thresh-
old supported robustness of a conclusion that esomeprazole
treatment is cost-effective. When work productivity costs were
included, results indicated that the esomeprazole strategy is 
cost-neutral. Extending the time horizon resulted in further cost-
effectiveness advantages for esomeprazole. CONCLUSION:
Esomeprazole 40mgod is cost-effective compared with generic
omeprazole 20mgod in the acute treatment of reﬂux esophagi-
tis in Sweden.
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OBJECTIVES: To determine the relative cost effectiveness of
proton pump inhibitor (PPI) based triple therapy regimens for
the eradication of Helicobacter pylori (H. pylori) in the primary
care setting in Ireland. METHODS: Using decision tree analysis
the expected cost for each H. pylori eradication strategy was
determined from the cost of each treatment option multiplied by
the probability of that option occurring. Only direct costs relat-
ing to the primary care setting such as GP consultation and 
medication costs, extracted from the Monthly Index of Medical
Specialties 2003, were included. Probabilities were obtained
using the GMS prescribing database where all patients who
received amoxycillin, clarithromycin and a PPI in the ERHA
region in 2002 were followed for one year. A broad range of clin-
ical and cost inputs was investigated by sensitivity analysis.
RESULTS: The main outcome measure was the cost per asymp-
tomatic patient for each therapeutic strategy. Depending on the
regimen adopted, 40.8% to 46.1% of patients did not require
any further medication in the year following H. pylori eradica-
tion treatment. The strategy of rabeprazole, amoxycillin and
clarithromycin was the most cost effective option with a cost of
€466 per asymptomatic patient. Two way sensitivity analysis
indicated that the cost of rabeprazole triple therapy and the dura-
tion of rabeprazole maintenance therapy would each have to
increase by 30% before this strategy ceased to be the most cost
effective option. CONCLUSION: This study indicates that the
triple therapy regimen of rabeprazole, amoxycillin and clar-
ithromycin is the most cost effective of the therapeutic strategies
examined for the treatment of H. pylori infection in the com-
munity setting in Ireland.
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OBJECTIVE: To determine the differences in indirect costs and
quality of life between persons affected by Crohn’s Disease (CD)
and those affected by Ulcerative Colitis (UC) as part of a cost of
IBD study in Germany. METHODS: Members of the German
Inﬂammatory Bowel Disease (IBD) Association (DCCV) were
recruited by post to prospectively document their IBD-associated
costs (sick leave, disability pensions, and medical resource use)
in a cost diary over 4 weeks. General demographic information
and IBD history were also reported. Health-Related Quality of
Life (hrQoL) was determined using the EuroQol EQ5-D. Indi-
rect costs were calculated according to national sources using the
human capital approach. RESULTS: Cost diaries were returned
by 483 persons (CD: 241; UC: 242) whose mean age was 42
years and average disease duration 13 years. Productivity losses
were reported by CD (14%) and UC (15%) subjects and average
sick leave was similar (CD: 1.2 days; UC: 1.5 days). However,
more CD (19%) than UC (7%) patients received a disability
pension. The mean 4-week indirect costs for CD were €266
(95%CI: 100, 433) higher than for UC (p < 0.002). The mean
hrQoL of CD subjects according to EuroQol VAS scores was 5
points lower (95%CI: -8.3, -1.7) than for UC subjects (p <
0.004). CONCLUSIONS: In Germany, indirect costs of CD are
signiﬁcantly higher than those of UC and hrQoL of CD patients
is signiﬁcantly lower than of UC patients. For CD, factors
decreasing occupational disability would decrease costs and since
hrQoL is also determined by the ability to work productively,
may improve hrQoL. Factors affecting indirect costs, which
account for a large part of the costs of IBD, can have a large
impact on the overall costs. Furthermore, these ﬁndings indicate
that determinants of costs must be searched for and evaluated
separately for each disease.
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